# Efferon

> Efferon manufactures multimodal hemoadsorption devices that remove endotoxins and inflammatory mediators directly from the bloodstream for adults and pediatric patients with sepsis, septic shock, and cytokine release syndrome. Efferon LPS and Efferon NEO are CE-marked in the European Union.

## Core pages
## EN (/)
- [Home](https://efferon.com/index.md): Company overview, sepsis statistics, clinical evidence, and global footprint.
- [About](https://efferon.com/about.md): Founders, leadership team, operations.
- [Technology](https://efferon.com/tech.md): Multimodal hemoadsorption — mechanism of action for endotoxin and cytokine removal.
- [Indications & Products](https://efferon.com/indications.md): Sepsis, septic shock, CRS, and indications in development.
## Application
- [Application](https://efferon.com/application.md): Device connection setup guides for CPB and RRT circuits.
- [Setup Guide for Integrating Efferon® Device into the Cardiopulmonary Bypass (CPB) Circuit](https://efferon.com/application/cpb.md): Setup guide.
- [Assembly of extracorporeal circuit with Efferon® device and hemofilter in “POSTfilter” mode on RRT machine](https://efferon.com/application/rrt-postfilter.md): Setup guide.
- [Assembly of extracorporeal circuit with Efferon® device and hemofilter in “PREfilter” mode on RRT machine](https://efferon.com/application/rrt-prefilter.md): Setup guide.
- [Assembly of extracorporeal circuit with Efferon® device in isolated hemoperfusion mode on RRT machine](https://efferon.com/application/rrt-hemoperfusion.md): Setup guide.
## Legal
- [Cookie Policy](https://efferon.com/cookie-policy.md)
- [Imprint](https://efferon.com/imprint.md)
- [Privacy Policy](https://efferon.com/privacy-policy.md)
- [Terms of Use](https://efferon.com/terms-of-use.md)
### Products
- [Efferon LPS](https://efferon.com/products/efferon-lps.md): Adult multimodal hemoadsorption device.
- [Efferon NEO](https://efferon.com/products/efferon-neo.md): Pediatric multimodal hemoadsorption device.
### News
- [Efferon on ESPNIC 2026](https://efferon.com/news/efferon-on-espnic-2026.md): 24 June 2026.
- [Efferon®NEO Receives CE MDR Mark](https://efferon.com/news/efferonneo-receives-ce-mdr-mark.md): 22 April 2026.
- [Efferon at ISICEM](https://efferon.com/news/efferon-at-isicem.md): 10 April 2026.
- [Efferon first distributors meeting](https://efferon.com/news/efferon-first-distributors-meeting.md): 08 April 2026.
- [Efferon is now available in Poland](https://efferon.com/news/efferon-is-now-available-in-poland.md): 11 March 2026.
- [Efferon®LPS is available in Costa Rica](https://efferon.com/news/efferonlps-is-available-in-costa-rica.md): 26 February 2026.
- [Efferon®LPS is now approved in Thailand](https://efferon.com/news/efferon-lps-is-now-approved-in-thailand.md): 18 February 2026.
- [Efferon LPS® incorporated into clinical guidelines of the German Society of Nephrology for therapeutic apheresis](https://efferon.com/news/efferon-lps-german-nephrology-guidelines-apheresis.md): 10 December 2025.
- [We’ll see each other in Greece](https://efferon.com/news/well-see-each-other-in-greece.md): 25 November 2025.
- [Efferon therapies are now available in Armenia!](https://efferon.com/news/efferon-therapies-are-now-available-in-armenia.md): 05 November 2025.
- [Clinical data confirmed the effectiveness of Efferon NEO in children with sepsis](https://efferon.com/news/clinical-data-confirmed-the-effectiveness-of-efferon-neo-in-children-with-sepsis.md): 30 October 2025.
- [Efferon LPS has been approved in the Kingdom of Saudi Arabia.](https://efferon.com/news/efferon-lps-has-been-approved-in-the-kingdom-of-saudi-arabia.md): 18 October 2025.
- [Extracorporeal removal of antibiotic drugs during Efferon LPS hemoadsorption is predictable and manageable](https://efferon.com/news/antibiotic-removal-during-efferon-lps-hemoadsorption.md): 09 October 2025.
- [Efferon at the 6th Asia Pacific AKI CRRT Congress in Bangkok](https://efferon.com/news/efferon-at-the-6th-asia-pacific-aki-crrt-congress-in-bangkok.md): 05 October 2025.
- [Win a New iPad! Join the Efferon LPS Photo Challenge on LinkedIn](https://efferon.com/news/win-a-new-ipad-join-the-efferon-lps-photo-challenge-on-linkedin.md): 12 September 2025.
- [Efferon LPS hemoadsorption device has been granted regulatory approval in the United Kingdom and Croatia.](https://efferon.com/news/efferon-lps-device-approval-uk-croatia.md): 23 July 2025.
- [Efferon LPS Now Available in Italy](https://efferon.com/news/efferon-lps-now-available-in-italy.md): 01 July 2025.
- [Applying Vicenza’s Lessons](https://efferon.com/news/applying-vicenzas-lessons.md): 28 June 2025.
- [Efferon Expands Its Global Presence](https://efferon.com/news/efferon-expands-its-global-presence.md): 23 June 2025.
- [Efferon expands to new markets with Bertossi partnership](https://efferon.com/news/efferon-expands-to-new-markets-with-bertossi-partnership.md): 06 June 2025.
- [Efferon LPS becomes available in Romania.](https://efferon.com/news/efferon-lps-becomes-available-in-romania.md): 25 May 2025.
- [New distribution agreements in European countries](https://efferon.com/news/distribution-agreements-in-european-countries.md): 22 July 2024.
- [Efferon LPS receives CE mark under EU MDR](https://efferon.com/news/efferon-lps-receives-ce-mark-under-eu-mdr.md): 29 April 2024.
- [Results of LASSO mRCT are published in Shock](https://efferon.com/news/results-of-lasso-mrct-published-in-shock.md): 20 April 2023.
- [Efferon at LIVES 2022 in Paris](https://efferon.com/news/efferon-at-lives-2022-in-paris.md): 03 November 2022.
- [Efferon has participated in MEDICA](https://efferon.com/news/efferon-participated-in-medica.md): 30 November 2021.
- [LASSO multicenter randomized trial launched](https://efferon.com/news/lasso-multicenter-randomized-trial-launched.md): 29 April 2021.
### Publications
- [Eferon LPS NEO hemoadsorption in pediatric sepsis patients: a multicenter controlled study](https://efferon.com/articles/eferon-lps-neo-pediatric-sepsis-multicenter-study.md): ESICM LIVES 2025. ICMx 13 (Suppl 1), 109 (2025). (2025).
- [Multimodal LPS-selective hemoadsorption combined with hemodiafiltration in the intensive care of gram-negative sepsis: a multicenter observational study.](https://efferon.com/articles/lps-hemoadsorption-hemodiafiltration-gram-negative-sepsis-study.md): General Reanimatology. 2025;21(6):4–12. (2025).
- [Hemoperfusion with Efferon LPS NEO device reverts multiple organ failure, decreases IL-6 and TNF levels and systemic immune inflammation in children with sepsis](https://efferon.com/articles/efferon-lps-neo-hemoperfusion-pediatric-sepsis-reverts-multiple-organ-failure.md): Critical Care 2024, 28(Suppl 1):P220 (2024).
- [Hemoperfusion using the LPS-selective mesoporous polymeric adsorbent in septic shock: a multicenter randomized clinical trial](https://efferon.com/articles/hemoperfusion-lps-mesoporous-polymeric-adsorbent-septic-shock-multicenter-rct.md): Shock. 2023 Jun 1;59(6):846-854 (2023).
- [Extracorporeal hemoperfusion with Efferon LPS for rapid reconstitution of vital parameters and decreasing proinflammatory biomarkers in patients with intra-abdominal sepsis](https://efferon.com/articles/efferon-lps-hemoperfusion-intra-abdominal-sepsis-biomarkers.md): Intensive Care Medicine Experimental 2022, 10(2): 000710 (2022).
- [Extracorporeal adsorption of cytokines in cytokine release syndrome in a patient with acute lymphoblastic leukemia after therapy with T cells with a chimeric antigen receptor. Clinical observation](https://efferon.com/articles/extracorporeal-cytokine-adsorption-crs-leukemia-car-t-case-clinical-observation.md): Therapeutic archive. 2021; 93 (7): 811-817 (2021).
- [Application of novel device Efferon LPS in hemoperfusion for simultaneous removal of endotoxin and cytokines in a patient with septic shock](https://efferon.com/articles/efferon-lps-hemoperfusion-simultaneous-endotoxin-cytokine-removal-septic-shock.md): World Journal of Medical Case Reports. Vol. 2, No. 3, 2021, pp. 46-50. (2021).
- [Hemosorption carried out by a column filled with hypercrosslinked styrene-divinibenzene copolymer with an immobilized LPS-selective ligand in a complex of intensive treatment of acute lung injury in the surgical treatment of lung cancer (clinical observation)](https://efferon.com/articles/hemosorption-styrene-divinylbenzene-copolymer-lps-ligand-acute-lung-injury-case.md): General resuscitation. 2020; 16 (4): 14-20. (2020).
- [Application of adsorbent based on a hypercrosslinked styrene-divinylbenzene copolymer with an immobilized LPS-selective ligand in hemoperfusion for the treatment of patients with septic shock](https://efferon.com/articles/adsorbent-styrene-divinylbenzene-copolymer-lps-ligand-hemoperfusion-sepsis.md): General resuscitation. 2020; 16 (6): 31-53. (2020).
- [Efficiency and safety of a new product for LPS-selective hemosorption (experimental study)](https://efferon.com/articles/efficiency-safety-new-lps-selective-hemosorption-product-experimental-study.md): General resuscitation. 2018; 14 (6): 51-60. (2018).
- [Polymeric sorbent, method for its production and use.](https://efferon.com/articles/polymeric-sorbent-method-for-production-and-use.md): Invention patent RU 2653125 C1. Date of registration: 23.05.2017 (2017).
- [Method for determination of bacterial endotoxin in biological fluids](https://efferon.com/articles/method-for-determination-of-bacterial-endotoxin-in-fluids.md): Invention patent RU 2691413 C1. Date of registration: 26.12.2017 (2017).
- [Methods for the determination of bacterial endotoxin in critical care medicine (review).](https://efferon.com/articles/methods-for-determination-of-bacterial-endotoxin-critical-care-review.md): General resuscitation. 2017; 13 (5): 109-120. (2017).
- [Sorbents for extracorporeal removal of toxic substances and molecules with unwanted biological activity (review)](https://efferon.com/articles/sorbents-for-extracorporeal-removal-of-toxic-substances-and-molecules-review.md): General resuscitation. 2016; 12 (6): 82-107. (2016).
## DE (/de/)
- [Home](https://efferon.com/de/index.md): Company overview, sepsis statistics, clinical evidence, and global footprint.
- [About](https://efferon.com/de/about.md): Founders, leadership team, operations.
- [Technology](https://efferon.com/de/tech.md): Multimodal hemoadsorption — mechanism of action for endotoxin and cytokine removal.
- [Indications & Products](https://efferon.com/de/indications.md): Sepsis, septic shock, CRS, and indications in development.
## Application
- [Application](https://efferon.com/de/application.md): Device connection setup guides for CPB and RRT circuits.
- [Einrichtungsanleitung für die Integration des Efferon®-Adsorbers in den kardiopulmonalen Bypass (CPB)-Kreislauf](https://efferon.com/de/application/cpb.md): Setup guide.
- [Aufbau des extrakorporalen Kreislaufs mit dem Efferon®-Adsorber und Hämofilter im Postfilter-Modus an einem Gerät für die Nierenersatztherapie](https://efferon.com/de/application/rrt-postfilter.md): Setup guide.
- [Aufbau des extrakorporalen Kreislaufs mit dem Efferon®-Adsorber und Hämofilter im Präfilter-Modus an einem Gerät für die Nierenersatztherapie](https://efferon.com/de/application/rrt-prefilter.md): Setup guide.
- [Aufbau des extrakorporalen Kreislaufs mit dem Efferon®-Adsorber im isolierten Hämoperfusionsmodus an einem Gerät für die Nierenersatztherapie](https://efferon.com/de/application/rrt-hemoperfusion.md): Setup guide.
## Legal
- [Cookie-Richtlinie](https://efferon.com/de/cookie-richtlinie.md)
- [Impressum](https://efferon.com/de/impressum.md)
- [Datenschutzerklärung](https://efferon.com/de/datenschutzerklarung.md)
- [Nutzungsbedingungen](https://efferon.com/de/nutzungsbedingungen.md)
### Products
- [Efferon LPS](https://efferon.com/de/products/efferon-lps.md): Erwachsene multimodal hemoadsorption device.
- [Efferon NEO](https://efferon.com/de/products/efferon-neo.md): Pädiatrisch multimodal hemoadsorption device.
### News
- [Efferon auf ESPNIC 2026](https://efferon.com/de/news/efferon-auf-espnic-2026.md): 24 June 2026.
- [Efferon®NEO erhält CE-MDR-Kennzeichnung](https://efferon.com/de/news/efferon-neo-erhaelt-ce-mdr-kennzeichnung.md): 22 April 2026.
- [Efferon auf dem ISICEM](https://efferon.com/de/news/efferon-beim-isicem.md): 10 April 2026.
- [Efferons erstes Distributor:innen-Treffen](https://efferon.com/de/news/erstes-distributoren-meeting-von-efferon.md): 08 April 2026.
- [Efferon ist jetzt in Polen verfügbar](https://efferon.com/de/news/efferon-ist-offiziell-in-polen-zugelassen.md): 11 March 2026.
- [Efferon®LPS jetzt in Costa Rica verfügbar](https://efferon.com/de/news/efferonlps-ist-in-costa-rica-erhaeltlich.md): 26 February 2026.
- [Efferon®LPS ist nun in Thailand zugelassen](https://efferon.com/de/news/efferon-lps-erhaelt-zulassung-in-thailand.md): 18 February 2026.
- [Efferon LPS® in klinische Leitlinien der Deutschen Gesellschaft für Nephrologie zur therapeutischen Apherese aufgenommen](https://efferon.com/de/news/efferon-lps-leitlinien-deutsche-gesellschaft-nephrologie-apherese.md): 10 December 2025.
- [Wir sehen uns in Griechenland](https://efferon.com/de/news/wir-sehen-uns-in-griechenland.md): 25 November 2025.
- [Efferon Therapien jetzt in Armenien verfügbar](https://efferon.com/de/news/efferon-therapien-jetzt-in-armenien-verfuegbar.md): 05 November 2025.
- [Klinische Daten bestätigen die Wirksamkeit von Efferon NEO bei Kindern mit Sepsis](https://efferon.com/de/news/klinische-daten-bestaetigen-wirksamkeit-efferon-neo-kinder-sepsis.md): 30 October 2025.
- [Efferon LPS wurde im Königreich Saudi-Arabien zugelassen](https://efferon.com/de/news/efferon-lps-zulassung-koenigreich-saudi-arabien.md): 18 October 2025.
- [Extrakorporale Elimination von Antibiotika während der Efferon-LPS-Hämoadsorption ist vorhersagbar und steuerbar](https://efferon.com/de/news/extrakorporale-elimination-antibiotika-efferon-lps-haemoadsorption.md): 09 October 2025.
- [Efferon auf dem 6. Asia Pacific AKI CRRT Congress in Bangkok](https://efferon.com/de/news/efferon-auf-dem-6-asia-pacific-aki-crrt-congress-in-bangkok.md): 05 October 2025.
- [Gewinnen Sie ein neues iPad! Nehmen Sie an der Efferon LPS Foto-Challenge auf LinkedIn teil](https://efferon.com/de/news/gewinnen-sie-ipad-efferon-lps-foto-challenge-linkedin.md): 12 September 2025.
- [Efferon LPS Hämoadsorptionsgerät erhält behördliche Zulassung im Vereinigten Königreich und in Kroatien](https://efferon.com/de/news/efferon-lps-haemoadsorption-zulassung-vereinigtes-koenigreich-kroatien.md): 23 July 2025.
- [Efferon LPS jetzt in Italien verfügbar](https://efferon.com/de/news/efferon-lps-jetzt-in-italien-erhaeltlich.md): 01 July 2025.
- [Learnings aus Vicenza in der Praxis](https://efferon.com/de/news/erkenntnisse-aus-vicenza-in-die-praxis-umsetzen.md): 28 June 2025.
- [Efferon erweitert seine globale Präsenz](https://efferon.com/de/news/efferon-erweitert-seine-globale-praesenz.md): 23 June 2025.
- [Efferon erschließt neue Märkte durch Partnerschaft mit Bertossi](https://efferon.com/de/news/efferon-erschliesst-neue-maerkte-durch-partnerschaft-mit-bertossi.md): 06 June 2025.
- [Efferon LPS jetzt auch in Rumänien verfügbar](https://efferon.com/de/news/efferon-lps-ist-ab-sofort-in-rumaenien-erhaeltlich.md): 25 May 2025.
- [Neue Vertriebsvereinbarungen in europäischen Ländern](https://efferon.com/de/news/neue-vertriebsvereinbarungen-in-europaeischen-laendern.md): 22 July 2024.
- [Efferon LPS erhält CE‑Kennzeichnung nach EU‑MDR](https://efferon.com/de/news/efferon-lps-erhaelt-ce-kennzeichnung-gemaess-eu-mdr.md): 29 April 2024.
- [Ergebnisse der LASSO-mRCT-Studie in Shock veröffentlicht](https://efferon.com/de/news/ergebnisse-der-lasso-mrct-in-shock-veroeffentlicht.md): 20 April 2023.
- [Efferon auf dem LIVES-Kongress 2022 in Paris](https://efferon.com/de/news/efferon-auf-der-lives-2022-in-paris.md): 03 November 2022.
- [Efferon nahm an der MEDICA teil](https://efferon.com/de/news/efferon-teilnahme-medica.md): 30 November 2021.
- [LASSO: multizentrische, randomisierte Studie gestartet](https://efferon.com/de/news/lasso-multizentrische-randomisierte-studie-gestartet.md): 29 April 2021.
### Publications
- [Multimodale LPS-selektive Hämoadsorption in Kombination mit Hämodiafiltration in der Intensivtherapie der gramnegativen Sepsis: eine multizentrische Beobachtungsstudie](https://efferon.com/de/articles/multimodale-lps-haemoadsorption-haemodiafiltration-gramnegative-sepsis-studie.md): General Reanimatology. 2025;21(6):4–12. (2025).
- [Hämoadsorption mit Eferon LPS NEO bei pädiatrischen Sepsispatienten: eine multizentrische kontrollierte Studie](https://efferon.com/de/articles/eferon-lps-neo-haemoadsorption-paediatrische-sepsis-multizentrische-studie.md): ESICM LIVES 2025. ICMx 13 (Suppl 1), 109 (2025). (2025).
- [Die Hämoperfusion mit dem Efferon LPS NEO-System führt bei Kindern mit Sepsis zur Rückbildung des Multiorganversagens und zur Senkung der IL-6-, TNF- und systemischen Entzündungswerte](https://efferon.com/de/articles/efferon-lps-neo-haemoperfusion-paediatrie-rueckbildung-multiorganversagen.md): Critical Care 2024, 28(Suppl 1):P220 (2024).
- [Hämoperfusion mit einem LPS-selektiven mesoporösen polymeren Adsorbens bei septischem Schock: eine multizentrische randomisierte klinische Studie](https://efferon.com/de/articles/haemoperfusion-lps-mesoporoeses-polymer-adsorbens-septischer-schock-rct.md): Shock. 2023 Jun 1;59(6):846-854 (2023).
- [Extrakorporale Hämoperfusion mit Efferon LPS zur schnellen Wiederherstellung der Vitalparameter und zur Senkung proinflammatorischer Biomarker bei Patienten mit intraabdominaler Sepsis](https://efferon.com/de/articles/efferon-lps-haemoperfusion-intraabdominale-sepsis-vitalparameter-biomarker.md): Intensive Care Medicine Experimental 2022, 10(2): 000710 (2022).
- [Extrakorporale Adsorption von Zytokinen beim Zytokin-Release-Syndrom bei einem Patienten mit akuter lymphoblastischer Leukämie nach Therapie mit T-Zellen mit chimärem Antigenrezeptor. Klinische Beobachtung](https://efferon.com/de/articles/extrakorporale-zytokinadsorption-crs-leukaemie-car-t-klinische-beobachtung.md): Therapeutic archive. 2021; 93 (7): 811-817 (2021).
- [Anwendung des neuartigen Geräts Efferon LPS zur Hämoperfusion bei gleichzeitiger Entfernung von Endotoxin und Zytokinen bei einem Patienten mit septischem Schock](https://efferon.com/de/articles/efferon-lps-haemoperfusion-entfernung-endotoxin-zytokine-septischer-schock.md): World Journal of Medical Case Reports. Vol. 2, No. 3, 2021, pp. 46-50. (2021).
- [Hämosorption mittels einer Säule, gefüllt mit hypervernetztem Styrol-Divinylbenzol-Copolymer mit immobilisiertem LPS-selektivem Liganden, in der Intensivtherapie des akuten Lungenversagens nach Lungenkrebsoperationen (klinische Beobachtung)](https://efferon.com/de/articles/haemosorption-styrol-divinylbenzol-copolymer-lps-ligand-lungenversagen-fall.md): General resuscitation. 2020; 16 (4): 14-20. (2020).
- [Anwendung eines Adsorbens auf Basis eines hypervernetzten Styrol-Divinylbenzol-Copolymers mit immobilisiertem LPS-selektivem Liganden in der Hämoperfusion zur Behandlung von Patienten mit septischem Schock](https://efferon.com/de/articles/adsorbens-styrol-divinylbenzol-copolymer-lps-ligand-haemoperfusion-sepsis.md): General resuscitation. 2020; 16 (6): 31-53. (2020).
- [Wirksamkeit und Sicherheit eines neuen Produkts zur LPS-selektiven Hämosorption (experimentelle Studie)](https://efferon.com/de/articles/wirksamkeit-sicherheit-neues-lps-selektives-haemosorption-produkt-studie.md): General resuscitation. 2018; 14 (6): 51-60. (2018).
- [Polymeres Adsorbens, Verfahren zu seiner Herstellung und Verwendung](https://efferon.com/de/articles/polymeres-adsorbens-verfahren-herstellung-verwendung.md): Invention patent RU 2653125 C1. Date of registration: 23.05.2017 (2017).
- [Methode zur Bestimmung bakterieller Endotoxine in biologischen Flüssigkeiten](https://efferon.com/de/articles/methode-bestimmung-bakterieller-endotoxine-biologische-fluessigkeiten.md): Invention patent RU 2691413 C1. Date of registration: 26.12.2017 (2017).
- [Methoden zur Bestimmung bakterieller Endotoxine in der Intensivmedizin (Übersichtsarbeit)](https://efferon.com/de/articles/methoden-bestimmung-bakterieller-endotoxine-intensivmedizin-uebersichtsarbeit.md): General resuscitation. 2017; 13 (5): 109-120. (2017).
- [Sorbentien zur extrakorporalen Entfernung toxischer Substanzen und von Molekülen mit unerwünschter biologischer Aktivität (Übersichtsarbeit)

](https://efferon.com/de/articles/entfernung-toxischer-substanzen-unerwuenschte-molekuele-uebersichtsarbeit.md): General resuscitation. 2016; 12 (6): 82-107. (2016).

## Optional

- [Full content dump](https://efferon.com/llms-full.txt): All pages concatenated as one markdown document.
- [Sitemap](https://efferon.com/sitemap.xml): XML sitemap of every page.

## Regulatory note

Efferon LPS and Efferon NEO are CE-marked in the European Union under EU MDR (Regulation 2017/745).